Indiana has a new name. With its growing field of precision medicine and life sciences, the state has secured the title of ...

Bristol Myers Squibb has opened its radiopharmaceutical manufacturing facility in Indianapolis, which played a major role in ...

The Bristol Myers Squibb subsidiary RayzeBio has opened a new 77,000-square-foot facility in Indianapolis, Indiana.

Bristol Myers Squibb is preparing to ship a new and possibly life-changing cancer treatment to patients across the world. The ...

Bristol Myers Squibb has opened a $160M radiopharma facility in Indianapolis, scaling up production since acquiring RayzeBio ...

Actithera’s radiopharma assets irreversibly bind to their targets, allowing for longer retention of the drug inside tumors.

Nuclidium has raised 79 million Swiss francs ($99 million) as the Swiss and German biotech looks to continue the clinical ...

6 月 2 日，百时美施贵宝（BMS）与 BioNTech 共同宣布达成一项全球性合作协议，双方将联合开发及商业化 BioNTech 旗下双特异性抗体候选药物 BNT327（原Biotheus的 PM8002），用于多种实体瘤治疗。根据协议内容，BioNTech 与 BMS 将协同推进这一临床候选药物的开发进程，这一合作动态在生物医药行业引发广泛关注。

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth ...

Nuclidium’s radiopharmaceutical platform is unique in its use of copper-based payloads, which the biotech claims can deliver higher doses while also being safer.